Open AccessEffects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis
Author(s) -
Mohamed A Yassin,
Ashraf T. Soliman,
Vincenzo De Sanctis,
Mohamed Abdel-Rahman,
Elsaid Bedair,
Manal M AbdElgawad
Publication year - 2014
Publication title -
indian journal of endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 28
eISSN - 2230-9500
pISSN - 2230-8210
DOI - 10.4103/2230-8210.137516
Subject(s) - medicine , osteoporosis , denosumab , bone mineral , rankl , endocrinology , receptor , activator (genetics)
Osteoporosis represents the second most common cause of endocrinopathy in patients with beta thalassemia major (BTM). Some drugs proved effective to reduce vertebral and non-vertebral fracture risk. Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor kappa B ligand (RANKL), a member of the tumor necrosis factor receptor superfamily essential for osteoclastogenesis. The efficacy and safety of denosumab in BTM-induced osteoporosis has not been tested.